Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: A phase II study

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 2, 2012, Pages 477-484

  Xenidis, N ^a   Chelis, L ^a   Amarantidis, K ^a   Chamalidou, E ^a   Dimopoulos, P ^a   Courcoutsakis, N ^a   Tentes, A ^b   Chiotis, A ^c   Prassopoulos, P ^a   Kakolyris, S ^a  

^a UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^b General Hospital of Didimotycho   (Greece)

^c General Hospital of Xanthi   (Greece)

Author keywords

Capecitabine; Docetaxel; Gemcitabine; Pancreatic cancer; Phase II

Indexed keywords

CAPECITABINE; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ASTHENIA; CANCER CONTROL; CLINICAL ARTICLE; CONJUNCTIVITIS; CONSTIPATION; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HAND FOOT SYNDROME; HUMAN; INOPERABLE CANCER; LIVER TOXICITY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; ONYCHOLYSIS; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HAND-FOOT SYNDROME; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUTROPENIA; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84856705596     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1717-6     Document Type: Review

References (25)

1. B Glimelius K Hoffman PO Sjoden, et al. 1996 Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 593 600 8879373 1:STN:280:DyaK2s%2FjtlOitw%3D%3D (Pubitemid 26285639)
2. HA Burris III MJ Moore J Andersen, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D (Pubitemid 27251144)
3. V Heinemann S Boeck A Hinke, et al. 2008 Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer BMC Cancer 8 82 18373843 10.1186/1471-2407-8-82 (Pubitemid 351552578)
4. T Conroy F Desseigne M Ychou, et al. 2011 Folfirinox versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817 1825 21561347 10.1056/NEJMoa1011923 1:CAS:528:DC%2BC3MXlvF2jsrw%3D
5. D Cunningham I Chau DD Stocken, et al. 2009 Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 5513 5518 19858379 10.1200/JCO.2009.24.2446 1:CAS:528:DC%2BC3cXhtVWitrc%3D
6. R Herrmann G Bodoky T Ruhstaller, et al. 2007 Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the swiss group for clinical cancer research and the central European cooperative oncology group J Clin Oncol 25 2212 2217 17538165 10.1200/JCO.2006.09.0886 1:CAS:528:DC%2BD2sXnsVShtbw%3D (Pubitemid 46954645)
7. G Lopes CMR Lima 2005 Docetaxel in the management of advanced pancreatic cancer Semin Oncol 32 10 23 10.1053/j.seminoncol.2005.04.003 (Pubitemid 40726040)
8. MH Kulke MA Tempero D Niedzwiecki, et al. 2009 Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904 J Clin Oncol 27 5506 5512 19858396 10.1200/JCO.2009.22.1309 1:CAS:528:DC%2BC3cXhtVWitrY%3D
9. Blaya M, Lopes Gl, Roman E et al (2007) Phase II trial of capecitabine and docetaxel as second line therapy for locally advanced and metastatic pancreatic cancer. ASCO Annual meeting (Abstract 15029)
10. ME Hill X Li S Kim, et al. 2011 A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (Mgtx) in previously untreated patients with metastatic adenocarcinoma of the pancreas Cancer Chemother Pharmacol 67 511 517 20461379 10.1007/s00280-010-1348-3 1:CAS:528: DC%2BC3MXitlamu7c%3D
11. De Jesus-Acosta A, Oliver G, Flores E et al (2010) A multicenter review of gemcitabine, docetaxel, and capecitabine (GTX) in patients with advanced pancreatic adenocarcinoma. ASCO Annual meeting (Abstract E14580)
12. RL Fine DR Fogelman SM Schreibman, et al. 2008 The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis Cancer Chemother Pharmacol 61 167 175 17440727 10.1007/s00280-007-0473-0 1:CAS:528:DC%2BD2sXhtFSrtbbK (Pubitemid 47512638)
13. Fine R, Moorer G, Sherman W et al (2009) Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. ASCO Annual meeting (Abstract 4623)
14. Dakik H, Moskovic D, Carlson P et al (2010) Evaluation of gemcitabine, docetaxel, capecitabine (GTX) in previously treated pancreatic cancer. ASCO Gastrointestinal Cancers Symposium (Abstract 221)
15. K Amarantidis K Houhouli K Papatheodorou, et al. 2006 A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors Oncol Res 16 281 287 17476973 1:CAS:528: DC%2BD2sXksVSju70%3D (Pubitemid 46568075)
16. A Trotti R Byhardt J Stetz, et al. 2000 Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy Int J Radiat Oncol Biol Phys 47 13 47 10758303 10.1016/S0360-3016(99)00559-3 1:STN:280:DC%2BD3c3itlCjsg%3D%3D (Pubitemid 30179675)
17. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
18. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10 2702835 10.1016/0197-2456(89)90015-9 1:STN:280:DyaL1M7ps1SjsQ%3D%3D (Pubitemid 19099520)
19. Pancreatic Adenocarcinoma V.2.2010 (2010) In national comprehensive cancer network. Practice guidelines in oncology
20. N Sawada T Ishikawa Y Fukase, et al. 1998 Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts Clin Cancer Res 4 1013 1019 9563897 1:CAS:528:DyaK1cXisFeksr4%3D (Pubitemid 28183404)
21. V Heinemann 2002 Gemcitabine-based combination treatment of pancreatic cancer Semin Oncol 29 25 35 11894005 10.1053/sonc.2002.30749 1:CAS:528:DC%2BD38XislOjtL4%3D (Pubitemid 34230196)
22. Q Ren V Kao JL Grem 1998 Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in Ht-29 colon cancer cells Clin Cancer Res 4 2811 2818 9829747 1:CAS:528:DyaK1cXns1Ogurc%3D (Pubitemid 28523510)
23. Norton L, Dugan U, Young Y et al (2005) Optimizing chemotherapeutic dose-schedule (Cds) by norton-simon modeling: capecitabine. In: Presented at the AACR meeting
24. W Scheithauer GV Kornek M Raderer, et al. 2002 Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer Ann Oncol 13 1583 1589 12377646 10.1093/annonc/dkf281 1:STN:280:DC%2BD38nitVWqsg%3D%3D (Pubitemid 35331455)
25. W Scheithauer GV Kornek M Raderer, et al. 2003 Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 21 1307 1312 12663719 10.1200/JCO.2003.09.016 1:CAS:528:DC%2BD2cXpsVWqsLk%3D (Pubitemid 46606408)